# continuing medical education

## Topical photodynamic therapy

Poljački M, Jovanović M, Matović LJ, Lugonja B, Gajić B, Roš T. Arch Oncol 2006;14(1-2):39-44.

#### Question 1.

Topical photodynamic therapy has been approved for the treatment of:

- a. Actinic keratoses
- b. Squamous cell carcinoma
- c. Psoriasis
- d. Viral warts

## Question 2.

Topical photosensitizer used for topical photodynamic therapy is:

- a. Porphyrine
- b. Delta aminolevulic acid
- c. Phthalocyanine
- d. Porphycene

## Question 3.

Protoporphyrin IX has maximal absorbtion wave-length:

- a. 630-1200 nm
- b. 540-800 nm
- c. 630-635 nm
- d. 200-630 nm

## Question 4.

Undesireable effect of topical photodynamic therapy in a form of erythema, edema, erosion and crusting occurs after:

- a. 2-6 weeks
- b. 6-8 weeks
- c. Immediately
- d. Within a week

In each question, there can be one or more than one correct answers

-						
Λ	n	21		••	6	•
n	ш	٥ı	N	51	э	•

Question 1.	a.	b.	C.	d.
Question 2.	a.	b.	C.	d.
Question 3.	a.	b.	C.	d.
Question 4.	a.	b.	C.	d.

Please circle correct answers and fill out a following application form:

Name:	
Medical speciality:	
Mailing address:	
City:	_ Zip code:
Country:	
E-mail:	
Signature:	Date:

## Instruction:

Please mail a copy of this page to *Archive of Oncology*, Editorial Office, Institute of Oncology Sremska Kamenica, Institutski put 4, 21204 Sremska Kamenica, Serbia, or fax it at +381 21 6613 741).

This page is also available on www.onk.ns.ac.yu/Archive/CME.pdf

# Deadline for submitting the answers is September 10, 2006

After several years of consideration the Editorial Board of the Archive of Oncology has decided to initiate a new heading in the journal titled Continuing Medical Education (CME). The aims were to popularize the idea of CME, to include it in the international system of medical education and Continuing Professional Development (CPD), and to form a database available to our readers. Through the cooperation with other centers for medical education, and European Credit Transfer System we are planning to introduce CME credit system. We would appreciate all suggestions, propositions, and new ideas you might have regarding CME and CPD.

# Current concepts of <sup>131</sup>I therapy in oncology: Indications, methods and follow-up

Mihailović J. Arch Oncol 2006;14(1-2):45-51

## Question 1.

Radioactive iodine as sodium iodide is used for the treatment of some thyroid malignant tumors. They are:

a. Anaplastic carcinoma

- b. Differentiated carcinoma
- c. Medullary carcinoma
- d. Intrathyroid lymphoma

## Question 2.

Radioactive isotope of iodine incorporated in metaiodobenzylguanidine (MIBG) used in the therapy of neuroblastoma and pheochromocytoma is:

a. <sup>123</sup> I			
b. <sup>125</sup>			
c. <sup>128</sup>			
d. <sup>131</sup> I			

# Question 3.

Application of Lipiodol labeled with radioactive iodine for the treatment of hepatocellular carcinoma (HCC) is:

a. Peroral

b. Subcutaneous

- c. Intravenous
- d. Intraarterial

#### Question 4.

Radioimmunotherapy with radiolabeled Rituximab is useful in the therapy of:

a. Prostate carcinoma

- b. Breast carcinoma
- c. Non-Hodgkin lymphoma
- d. Malignant brain tumors

In each question, there can be one or more than one correct answers

## Answers:

Question 1.	a.	b.	C.	d.
Question 2.	a.	b.	C.	d.
Question 3.	a.	b.	С.	d.
Question 4.	a.	b.	C.	d.

Please	circle	correct	answers	and	fill	out	a	following	application	form:
--------	--------	---------	---------	-----	------	-----	---	-----------	-------------	-------

Name:		_			
Medical speciality:		_			
Mailing address:					
		_			
City:	Zip code:				
Country:					
E-mail:		_			
Signature:	Date:				

## Instruction:

Please mail a copy of this page to *Archive of Oncology*, Editorial Office, Institute of Oncology Sremska Kamenica, Institutski put 4, 21204 Sremska Kamenica, Serbia, or fax it at +381 21 6613 741).

This page is also available on www.onk.ns.ac.yu/Archive/CME.pdf

#### Deadline for submitting the answers is September 10, 2006

After several years of consideration the Editorial Board of the Archive of Oncology has decided to initiate a new heading in the journal titled Continuing Medical Education (CME). The aims were to popularize the idea of CME, to include it in the international system of medical education and Continuing Professional Development (CPD), and to form a database available to our readers. Through the cooperation with other centers for medical education, and European Credit Transfer System we are planning to introduce CME credit system. We would appreciate all suggestions, propositions, and new ideas you might have regarding CME and CPD.